TY -的T1 -比较重症肌无力的临床和实验室特征在不同种族、性别和年龄组。(p5.4 - 034) JF 首页-神经学乔-神经学六世- 92 - 15补充SP - p5.4 - 034 AU - Shabnam Pakneshan AU - Kamal Shouman盟莎拉Razmjou AU -罗伯特Lisak Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p5.4 - 034. -抽象N2 -目的:识别肌无力的种族差异在临床和实验室特征gravisBackground:临床和实验室特征之间的复杂关系重症肌无力(MG)和性别和种族被发现在先前的研究中,然而这种差异的相关性已经很少了。本研究旨在检测MG的种族差异在临床和实验室特征。设计/方法:回顾性横断面研究的所有成年人MG在两个主要医院。人口数据包括但不限于种族、年龄、性别、和血清学标记(乙酰胆碱受体(乙酰胆碱受体),肌肉特定激酶(麝香)和Straitional肌肉(Str)抗体)被收集。统计分析与皮尔逊卡方检验和方差分析被执行。P-values < 0.05 were considered statistically significant.Results: 113 patients were identified. 54.8% of patients were women. 78 patients (69%) had AChR, 10 (8.84%) had MuSK. 52 patients were tested for both antibodies, 6 (5.3%) were double positive and 19 (16.81%) were double negative. 62% of AChR patients were white (p >0.05). Of the 10 MuSK patients, 6 were African American, 3 other races and one white (p< 0.05). 90% of patients with MuSK (9/10) were women (p< 0.05). No statistically significant difference was found in gender distribution of AChR. 64 patients were tested for Str, in 25 with positive results, 76% were African American (p< 0.05). None of the MuSK patients was Str positive. Of 10 MuSK patients, 9 had generalized and one had ocular myasthenia (p < 0.05). 65% of AchR patients had generalized MG and 35% had ocular MG (p>0.05).Conclusions: The results of this study support the existence of racial differences in clinical and laboratory features of myasthenia gravis. Further studies of genetic factors affecting clinical features of myasthenia gravis is beneficial.Disclosure: Dr. Pakneshan has nothing to disclose. Dr. Shouman has nothing to disclose. Dr. Razmjou has nothing to disclose. Dr. Lisak has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with: Alexion, Argenix, Novartis Pharmaceuticals, Syntimmune, Teva Pharmaceuticals, Clearview Consulting, Destum, GLG Consulting, Haven Consulting, Informa Consulting, Insights Pharma Consulting, and Slingshot Consulting. Dr. Lisak has received research support from: Catalyst Pharmaceuticals, Chugai, Genentec/Roche, Mallinckdrot, Medimune, Novartis Pharmaceuticals, Ra Pharmaceuticals, and Teva Pharmaceuticals. ER -